MDMB-CHMINACA

MDMB-CHMINACA (also known as MMB-CHMINACA) is a synthetic cannabinoid and indazole-based cannabinoid that is presumed to be a potent agonist of the CB1 receptor. It was first identified in Japan in 2014.

History

MDMB-CHMINACA was first identified in Japan in 2014. It was initially developed by Pfizer in 2008, although it is unclear whether it was ever used for medicinal purposes. It is part of a series of indazole-based synthetic cannabinoids.

Pharmacology

MDMB-CHMINACA is believed to be a potent agonist of the CB1 receptor, although the exact mechanism of action is not fully understood. It is structurally related to other synthetic cannabinoids such as AB-CHMINACA and AB-FUBINACA, but is reported to be more potent.

Legal status

The legal status of MDMB-CHMINACA varies by country. In the United States, it is a Schedule I controlled substance. It is also controlled in China and many European countries.

Health effects

The health effects of MDMB-CHMINACA are not well-studied. However, synthetic cannabinoids in general are known to be potentially harmful and can cause a variety of adverse effects, including seizures, psychosis, and death.

See also

• Synthetic cannabinoids
• Indazole
• Cannabinoid receptor

MDMB-CHMINACA Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.

Translate to: East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski